figshare
Browse
Figure_2.tif (598.2 kB)

Ceacam1 regulates GVHD target organ damage.

Download (0 kB)
figure
posted on 2011-07-06, 02:40 authored by Sydney X. Lu, Lucy W. Kappel, Anne-Marie Charbonneau-Allard, Renée Atallah, Amanda M. Holland, Claire Turbide, Vanessa M. Hubbard, Jimmy A. Rotolo, Marsinay Smith, David Suh, Christopher King, Uttam K. Rao, Nury Yim, Johanne L. Bautista, Robert R. Jenq, Olaf Penack, Il-Kang Na, Chen Liu, George Murphy, Onder Alpdogan, Richard S. Blumberg, Fernando Macian, Kathryn V. Holmes, Nicole Beauchemin, Marcel R. M. van den Brink

A) 5×106 TCD-BM ± 1×106 T→BALB/c. Day 21. Histopathology score. N = 5–12/group. SB, small bowel. LB, large bowel. B) Thymocyte count and apoptotic skin cells from (A). N≥7/group. Day 21. One of two representative experiments. C) Apoptotic skin cells from (A). N≥7/group. Day 21. D) 5×106 TCD-BM ± 1×106 T→BALB/c. Histopathology score. Day 21. N≥7/group. SB, small bowel. LB, large bowel. E) Thymocyte counts from (E): N≥7/group. One of two independent experiments. DP: CD4+CD8+ double-positive thymocytes. Day 21. F) Apoptotic skin cells from (E). N≥7/group. Day 21. G) 5×106 TCD-BM ± 1×106 T→WT or Ceacam1−/− BALB/c. Histopathology score. Day 14. N≥12/group. SB, small bowel. LB, large bowel. H) Thymocyte count from (I). N≥8/group. One of two independent experiments. DP: CD4+CD8+ double-positive thymocytes. Day 14.

History

Usage metrics

    PLOS ONE

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC